- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01766960
Altered Drug Disposition and Biomarkers for Diagnosis of Chronic Inflammatory Liver Disease
March 2, 2016 updated by: Sidney Barritt, MD, University of North Carolina, Chapel Hill
Altered Drug Disposition and Biomarkers for Diagnosis of Chronic Inflammatory Liver Disease.
One-third of the U.S. population suffers from non-alcoholic fatty liver disease (NAFLD).
NAFLD is caused by diabetes and obesity, and is becoming more common.
Although many people have this disease, the change in how the liver handles drugs and compounds in the body has not been studied.
The purpose of this study is to investigate how advanced NAFLD changes the ability of the liver to handle both endogenous and exogenous compounds.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
22
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- North Carolina Clinical and Translational Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
General:
- Man or woman between 18 and 65 years of age
- Negative pregnancy test for women of childbearing potential
- Negative urine drug screen
Healthy Subjects:
- Normal liver function tests
- Normal kidney function and lipid panel
Nonalcoholic Steatohepatitis Patients:
- Recent liver biopsy with nonalcoholic fatty liver disease activity score at least 4
Exclusion Criteria:
General:
- History of significant alcohol use (>20 g/day) and/or illicit drug use
- Inability to abstain from alcohol for 48 prior to study
- Use of drugs associated with a clinical or histological picture consistent with fatty liver disease or NASH for more than 12 consecutive weeks in the year prior to screening; these include amiodarone, tamoxifen, methotrexate, glucocorticoids, anabolic steroids, tetracyclines, estrogens (at doses greater than those used for hormone replacement) or valproate/valproic acid
- Type 2 diabetes treated with oral agents other than metformin; these include secretagogues, thiazolidinediones, alpha-glucosidase inhibitors, exenatide and pramlintide.
- Current or recent use of bile acid sequestrants, bile acid derivatives (i.e. ursodiol) or fibric acid derivatives.
- Current use of antioxidants such as silymarin, vitamin C, glutathione, or non-prescribed complementary alternative medications (including dietary supplements, megadose vitamins, herbal preparations, and special teas) within 30 days prior to screening.
- Previous liver biopsy that demonstrated presence of cirrhosis.
- Radiologic imaging consistent with cirrhosis or portal hypertension.
- Serum creatinine of 2.0 mg/dL or greater, or on dialysis, at screening.
- History of immunologically mediated disease (e.g., inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, severe psoriasis, rheumatoid arthritis) that could affect the assessment of biomarkers (bile acids or inflammation).
- History of bariatric surgery.
- BMI > 45 kg/m^2 at screening.
- Any known hypersensitivity to opiates, opiate antagonists, or ondansetron.
Healthy Subjects:
- Taking concomitant medications, both prescription and non-prescription (including herbal products and over-the-counter medications), other than oral contraceptives and multivitamins (women stabilized on hormonal methods of birth control will be allowed to participate)
- History or other evidence of liver disease in the opinion of the study investigators.
- BMI > 30 kg/m^2 at screening.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Healthy volunteers
Subjects will be asked to fast overnight.
Upon presentation, FibroScan procedure with CAP will be conducted and baseline and postprandial bile acid profile will be assessed.
Then, intravenous morphine will be administered and the pharmacokinetic profile will be assessed over 8 hours.
|
A high fat breakfast will be administered to induce gall bladder emptying.
Five milligrams of intravenous morphine will be administered.
|
Experimental: Advanced nonalcoholic fatty liver disease patients
Subjects will be asked to fast overnight.
Upon presentation, FibroScan procedure with CAP will be conducted and baseline and postprandial bile acid profile will be assessed.
Then, intravenous morphine will be administered and the pharmacokinetic profile will be assessed over 8 hours.
|
A high fat breakfast will be administered to induce gall bladder emptying.
Five milligrams of intravenous morphine will be administered.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic profile of morphine and its hepatically derived metabolites.
Time Frame: 8 hours post dose
|
Morphine will be administered as a 5-min IV infusion.
Pharmacokinetic profiles of morphine and morphine metabolites will be quantified in the serum over the 8-hour sampling period.
Non-compartmental analysis will be performed using Pharsight Phoenix software, comparing the following parameters between healthy subjects and patients with advanced NAFLD.
The maximal concentration, time of maximal concentration, elimination half-life, area under the curve, and systemic and renal clearances will be calculated for both morphine and the glucuronide metabolites.
Volume of distribution and metabolic clearance will be calculated for morphine.
|
8 hours post dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bile acid profile
Time Frame: Pre- and postprandially
|
The bile acid profile in healthy and diseased subjects will be assessed following an 8 hour fast and every 30 min for 2 hours following a high fat breakfast.
At each of the 5 time points, serum concentrations of total and selected individual bile acid species will be quantified and compared between healthy subjects and patients with advanced NAFLD.
Comparison of the bile acid profile, comprised of all selected bile acids, between subjects and patients will pose as the primary endpoint for this outcome.
|
Pre- and postprandially
|
FibroScan with Controlled Attenuation Parameter (CAP) Software
Time Frame: No preparation (fasting) required-consumption of large meals prior to the Fibroscan procedure is not advised
|
FibroScan is more sensitive method to identify less severe scarring of liver tissue when compared to liver ultrasound and contrary to liver biopsy, it is not invasive.
In this study, Fibroscan will be used to assess the extent of liver fibrosis in both healthy volunteers and patients diagnosed with NAFLD and the CAP software will be used to estimate fat liver content.
These findings will be correlated with changes in morphine disposition and bile acid profile observed in the study participants as described above.
|
No preparation (fasting) required-consumption of large meals prior to the Fibroscan procedure is not advised
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Alfred S Barritt, MD, University of North Carolina, Chapel Hill
- Principal Investigator: Kim LR Brouwer, PharmD, PhD, University of North Carolina, Chapel Hill
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2012
Primary Completion (Actual)
March 1, 2014
Study Completion (Actual)
June 1, 2014
Study Registration Dates
First Submitted
January 4, 2013
First Submitted That Met QC Criteria
January 9, 2013
First Posted (Estimate)
January 11, 2013
Study Record Updates
Last Update Posted (Estimate)
March 3, 2016
Last Update Submitted That Met QC Criteria
March 2, 2016
Last Verified
March 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12-1599
- 550KR41202 (Other Grant/Funding Number: NC TraCS Institute)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fatty Liver
-
Shiraz University of Medical SciencesCompletedFatty Liver | Fatty Liver, NonalcoholicIran, Islamic Republic of
-
Hoffmann-La RocheCompletedFatty Liver, Non-alcoholic Fatty Liver Disease, NAFLDGermany, Austria
-
GenfitTerminatedNon-Alcoholic Fatty LiverNetherlands
-
Medical College of WisconsinENDRA Life Sciences, Inc.RecruitingFatty Liver | NAFLD | Non-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis | Non-alcoholic Fatty Liver | NASH | Fatty Liver DiseaseUnited States
-
Cairo UniversityRecruitingNon-Alcoholic Fatty Liver DiseaseEgypt
-
Miriam Vos, MDImmuron Ltd.; Advanced MR Analytics ABCompletedNonalcoholic Fatty Liver Disease (NAFLD)United States
-
Nehal Abou SeadaCompletedNon-Alcoholic Fatty Liver Disease
-
HaEmek Medical Center, IsraelTerminatedPatients With Fatty Liver DiseaseIsrael
-
AB Biotics, SACompletedNon Alcoholic Fatty LiverMexico
-
University of L'AquilaRecruitingNAFLD- Non Alcoholic Fatty Liver DiseaseItaly
Clinical Trials on High fat meal
-
USDA, Western Human Nutrition Research CenterTerminatedObesity | Overweight | Body WeightUnited States
-
Agroscope Liebefeld-Posieux Research Station ALPCompletedObesity | Nutritional InterventionSwitzerland
-
Pennington Biomedical Research CenterCompletedDiabetes Mellitus, Type 2United States
-
Hospital Universitari Vall d'Hebron Research InstituteCompleted
-
Universidad IcesiUniversidad de San BuenaventuraCompletedCardiovascular DiseasesColombia
-
Wageningen UniversityTop Institute Food and NutritionCompletedCardiovascular Disease | Endothelial DysfunctionNetherlands
-
University of ReadingUnilever R&DCompletedCardiovascular DiseaseUnited Kingdom
-
University of Missouri-ColumbiaCompleted
-
Virginia Commonwealth UniversitySigma XiCompletedLipemia | Cardiovascular Risk FactorUnited States
-
Wageningen UniversityDutch Dairy Organization (NZO)CompletedCardiovascular Disease | The Metabolic SyndromeNetherlands